The Effect of Food and the Proton Pump Inhibitor Rabeprazole on Binimetinib Pharmacokinetics in Healthy Participants.
Erik Hahn, Joseph Piscitelli, Dustin Huynh et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial assessed the impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of binimetinib in healthy participants. The study found no clinically significant changes in binimetinib pharmacokinetics due to either low-fat or high-fat meals, or rabeprazole. The peak plasma concentration increased by 29% with a low-fat meal and decreased by 17.2% with a high-fat meal.
Key findings
- The area under the plasma concentration-time curve for binimetinib remained unchanged with low-fat and high-fat meals.
- Peak plasma concentration of binimetinib increased by 29% with a low-fat meal.
- Rabeprazole increased the area under the plasma concentration-time curve by 4% but decreased maximum concentration by 17.4%.
Why it matters
Understanding the pharmacokinetics of binimetinib in relation to food and proton pump inhibitors is crucial for optimizing treatment regimens in patients with BRAF-mutant melanoma and non-small cell lung cancer, ensuring effective drug absorption and minimizing interactions.